• Tamara Bezek, Jasna Bingulac-Popović, Dinko Bagatin, Roberta Petlevski, and Irena Jukić.
• 1Molecular Diagnostics Department, Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 2Bagatin Clinic, Zagreb, Croatia; 3Faculty of Dental Medicine and Health in Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia; 5Medical Department, Croatian Institute of Transfusion Medicine, Zagreb, Croatia; 6Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
• Acta Clin Croat. 2022 Feb 1; 60 (3): 354-360.

AbstractABO blood group is a risk factor for several cancers, but it is not clear yet whether the risk of breast cancer is greater in particular ABO blood type carriers. The aim of this case-control study was to examine the correlation between ABO blood group genotypes, estrogen receptor (ER), progesterone receptor (PR) and HER2 status as tumor grade markers (I-III), and the occurrence of breast cancer. The research included 59 patients with invasive breast cancer and 80 asymptomatic, healthy women, blood donors. Genomic DNA was isolated using QIAampDNA Blood Mini Kit (QIAGEN, Germany). Genotyping was performed using in-house polymerase chain reaction with sequence-specific primers (PCR-SSP) method. Comparison of genotypes and phenotypes of ABO blood groups between patients and control group yielded p>0.05. There was no statistical significance of correlation between ABO genotypes/phenotypes in either patient group or control group. Testing the significance of different tumor grade occurrence, and ER, PR and HER2/neu status showed no statistical significance ​​in the occurrence of a particular tumor grade, or in ER, PR and HER2/neu status as tumor markers in O1A1 genotype compared to non-O1A1 genotypes. Our study results confirmed that there was no correlation between ABO blood type genotypes/phenotypes and breast cancer in study groups.

15 keywords...

hide…